Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months
August 29 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International, Inc.
Reports Revenues Up 850%
for
Q2 and
850% for 1st 6
months
OCEANSIDE, CA --
August 29, 2019 -- InvestorsHub NewsWire
-- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) reported that its
second-quarter 2019 revenues rose 1,000% percent for the
first 6-month
period as
compared to the same period in 2018.
These increases were
due primarily to the commercialization of NanoStilbene and
releasing it for sale after completing our clinical program that
included a pharmacokinetic trial and a pilot cancer study in
advanced cancer patients using 300mg of nanoparticle pterostilbene.
The results of this clinical trial have
been
submitted to a medical journal for peer review and ultimately for
final publication. This represented 4 years of work to develop,
patent, manufacture, test, and publish the results of this study
which showed a substantial increase in activity of T cells and NK
cells as a result of treatment with NanoStilbene.
It is known that NK
cells, termed natural killer cells, are the first line of defense
against cancer, while T cells provide immunological memory that
prevents cancer from coming back. Mechanistically,
the authors believed that an increase in immune response was the
result of immune suppression in cancer-associated inflammation by
NanoStilbeneā¢ [1]. The
active ingredient in NanoStilbeneā¢, called pterostilbene, is a
potent inhibitor of inflammation and this study gives clear
evidence.
We anticipate that
when these results are published and made public our sales will
increase substantially. NanoStilbene is a very cost-effective
nutraceutical adjuvant that has now been shown clinically to be
safe and effective at reducing inflammation caused by cancers and
at the same time increasing the immune system's ability to fight
cancer on its own by way of NK cell
population increase.
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
[1] https://mynanostilbene.com
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or
"project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024